デフォルト表紙
市場調査レポート
商品コード
1547860

ファーマコビジランスの世界市場調査レポート:産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Pharmacovigilance Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032


出版日
ページ情報
英文 170 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ファーマコビジランスの世界市場調査レポート:産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 170 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ファーマコビジランス市場の世界需要は、2023年の88億3,000万米ドルから2032年には約193億米ドルの市場規模に達すると推定され、調査期間2024~2032年のCAGRは9.08%です。

ファーマコビジランスは、医薬品による副作用やその他の薬剤関連問題の検出、収集、評価、理解、監視、予防に関連する科学です。副作用(ADR)とは、臨床使用中に生じた医薬品の有害または有害な反応のことです。副作用には、薬剤毒性を含む様々な種類があります。ファーマコビジランスは、医薬品の有害な影響を理解し、特定し、患者のリスクを軽減することを目的としています。ファーマコビジランスは、医薬品の発見・開発手順において避けられないものです。医薬品の消費量の増加に伴い、適切なファーマコビジランスの必要性も加速しています。

市場力学

世界のファーマコビジランス市場を牽引している主要要因には、医薬品消費の拡大、急速に進歩する創薬・開発、副作用・薬毒性の増加などがあります。さらに、個別化医療への嗜好の高まりや、ファーマコビジランスサービスのアウトソーシング傾向の高まりといった動向も、世界市場を促進すると予想されます。情報システムやADRデータベースの進歩も、ファーマコビジランス市場の成長を支えています。COVID-19パンデミックは、世界の製薬メーカーがこの病気に対する薬剤の発見に精力的に取り組んでいることから、予測期間中、市場をより精力的に刺激すると予想されます。しかし、サプライチェーンの混乱は、しばらくの間、世界市場を混乱させる可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、ファーマコビジランスの世界市場における各セグメントを包括的に評価することもできます。ファーマコビジランス産業の成長と動向は、この調査に全体的なアプローチを記載しています。

市場セグメンテーション

ファーマコビジランス市場レポートのこのセクションでは、国と地域レベルのセグメントに関する詳細なデータを提供し、それによって戦略家が今後の機会でそれぞれの製品やサービスの対象層を特定するのに役立ちます。

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカのファーマコビジランス市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、このレポートでは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。

ご要望がございましたら、弊社までご連絡ください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 ファーマコビジランス-産業分析

  • イントロダクション:市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカー一覧
    • 主要原材料の価格動向
  • 潜在的バイヤー一覧
  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネル発展動向

第5章 ファーマコビジランスの世界市場分析:医薬品開発別

  • 医薬品開発別概要
  • 実績データと予測データ
  • 医薬品開発別分析
  • 前臨床試験
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIVまたは市販後調査

第6章 ファーマコビジランスの世界市場分析:手法タイプ別

  • 手法タイプ別概要
  • 実績データと予測データ
  • 手法タイプ別分析
  • 自発的報告
  • ADR報告の強化
  • 対象自発報告
  • コホートイベントモニタリング
  • マイニング

第7章 世界のファーマコビジランス市場分析:サービスタイプ別

  • サービスタイプ別概要
  • 実績データと予測データ
  • サービスタイプ別分析
  • 社内
  • アウトソーシング契約

第8章 ファーマコビジランスの世界市場分析:地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米:セグメント別
    • 北米:国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州:セグメント別
    • 欧州:国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋:セグメント別
    • アジア太平洋:国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ:セグメント別
    • ラテンアメリカ:国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ:セグメント別
    • 中東・アフリカ:国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第9章 ファーマコビジランス企業の競合情勢

  • ファーマコビジランス市場の競合
  • 提携/協力/合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Accenture Plc
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant
  • Labcorp Drug Development
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • ICON Plc
  • IGATE Corporation
  • IMEDGlobal Corporation
  • Syneos Health
  • Novartis AG
  • Parexel International Corporation
  • Pfizer Inc.
  • Pharmaceutical Product Development LLC.(PPD)
  • IQVIA
  • Sanofi
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Development (USD MN)
  • Preclinical Studies Market Sales By Geography (USD MN)
  • Phase I Market Sales By Geography (USD MN)
  • Phase II Market Sales By Geography (USD MN)
  • Phase III Market Sales By Geography (USD MN)
  • Phase IV or Post Marketing Surveillance Market Sales By Geography (USD MN)
  • Analysis By Type of Methods (USD MN)
  • Spontaneous Reporting Market Sales By Geography (USD MN)
  • Intensified ADR Reporting Market Sales By Geography (USD MN)
  • Targeted Spontaneous Reporting Market Sales By Geography (USD MN)
  • Cohort Event Monitoring Market Sales By Geography (USD MN)
  • EHR Mining Market Sales By Geography (USD MN)
  • Analysis By Type of Service (USD MN)
  • In-house Market Sales By Geography (USD MN)
  • Contract Outsourcing Market Sales By Geography (USD MN)
  • Global Pharmacovigilance Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Pharmacovigilance Report
  • Market Research Process
  • Market Research Methodology
  • Global Pharmacovigilance Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Development
  • Market Attractiveness Analysis By Type of Methods
  • Market Attractiveness Analysis By Type of Service
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Development (USD MN)
  • Preclinical Studies Market Sales By Geography (USD MN)
  • Phase I Market Sales By Geography (USD MN)
  • Phase II Market Sales By Geography (USD MN)
  • Phase III Market Sales By Geography (USD MN)
  • Phase IV or Post Marketing Surveillance Market Sales By Geography (USD MN)
  • Global Market Analysis By Type of Methods (USD MN)
  • Spontaneous Reporting Market Sales By Geography (USD MN)
  • Intensified ADR Reporting Market Sales By Geography (USD MN)
  • Targeted Spontaneous Reporting Market Sales By Geography (USD MN)
  • Cohort Event Monitoring Market Sales By Geography (USD MN)
  • EHR Mining Market Sales By Geography (USD MN)
  • Global Market Analysis By Type of Service (USD MN)
  • In-house Market Sales By Geography (USD MN)
  • Contract Outsourcing Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11212767

The global demand for Pharmacovigilance Market is presumed to reach the market size of nearly USD 19.3 Billion by 2032 from USD 8.83 Billion in 2023 with a CAGR of 9.08% under the study period 2024-2032.

Pharmacovigilance is a science related to the detection, collection, assessment, understanding, monitoring, and prevention of adverse effects or any other drug-related problem with the pharmaceutical products. An adverse drug reaction (ADR) is an adverse or harmful reaction of medicines that occurred during its clinical use. The adverse reaction may be of various types including drug toxicity. Pharmacovigilance deals with understanding and identifying the harmful effects of pharmaceutical products and aids in reducing the risk to the patients. Pharmacovigilance is an unavoidable part of drug discovery and development procedures. With the growing consumption of medicines, the need for the proper pharmacovigilance is also accelerated.

MARKET DYNAMICS

The prime forces that are driving the global pharmacovigilance market include growing drug consumption, rapidly advancing drug discovery and development, and rising incidences of adverse drug reactions & drug toxicity. Furthermore, factors such as a growing preference for personalized medicine and a rising trend for outsourcing pharmacovigilance services are expected to foster the global market. The advancement in information systems and ADR databases is also supporting the growth of the pharmacovigilance market. COVID-19 pandemic is anticipated to stimulate the market more energetically, during the forecast period, as the global pharmaceutical manufacturers are working strenuously to discover the drug against the disease. However, supply chain disruption may agitate the global market for some period.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Pharmacovigilance. The growth and trends of Pharmacovigilance industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Pharmacovigilance market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Development

  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV or Post Marketing Surveillance

By Type of Methods

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

By Type of Service

  • In-house
  • Contract Outsourcing

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pharmacovigilance market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmacovigilance market include Accenture Plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant, Labcorp Drug Development, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, ICON Plc, IGATE Corporation, IMEDGlobal Corporation, Syneos Health, Novartis AG, Parexel International Corporation, Pfizer Inc., Pharmaceutical Product Development LLC. (PPD), IQVIA, Sanofi,. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. PHARMACOVIGILANCE - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Development
    • 3.7.2 Market Attractiveness Analysis By Type of Methods
    • 3.7.3 Market Attractiveness Analysis By Type of Service
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY DRUG DEVELOPMENT

  • 5.1. Overview By Drug Development
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Drug Development
  • 5.4. Preclinical Studies Historic and Forecast Sales By Regions
  • 5.5. Phase I Historic and Forecast Sales By Regions
  • 5.6. Phase II Historic and Forecast Sales By Regions
  • 5.7. Phase III Historic and Forecast Sales By Regions
  • 5.8. Phase IV or Post Marketing Surveillance Historic and Forecast Sales By Regions

6. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY TYPE OF METHODS

  • 6.1. Overview By Type of Methods
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Type of Methods
  • 6.4. Spontaneous Reporting Historic and Forecast Sales By Regions
  • 6.5. Intensified ADR Reporting Historic and Forecast Sales By Regions
  • 6.6. Targeted Spontaneous Reporting Historic and Forecast Sales By Regions
  • 6.7. Cohort Event Monitoring Historic and Forecast Sales By Regions
  • 6.8. EHR Mining Historic and Forecast Sales By Regions

7. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY TYPE OF SERVICE

  • 7.1. Overview By Type of Service
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Type of Service
  • 7.4. In-house Historic and Forecast Sales By Regions
  • 7.5. Contract Outsourcing Historic and Forecast Sales By Regions

8. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PHARMACOVIGILANCE COMPANIES

  • 9.1. Pharmacovigilance Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF PHARMACOVIGILANCE INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Accenture Plc
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Bristol-Myers Squibb
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Clinquest Group B.V.
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Cognizant
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Labcorp Drug Development
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. F. Hoffmann-La Roche Ltd.
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. GlaxoSmithKline Plc
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. ICON Plc
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. IGATE Corporation
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. IMEDGlobal Corporation
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. Syneos Health
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. Novartis AG
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments
  • 10.15. Parexel International Corporation
    • 10.15.1 Company Overview
    • 10.15.2 Company Revenue
    • 10.15.3 Products
    • 10.15.4 Recent Developments
  • 10.16. Pfizer Inc.
    • 10.16.1 Company Overview
    • 10.16.2 Company Revenue
    • 10.16.3 Products
    • 10.16.4 Recent Developments
  • 10.17. Pharmaceutical Product Development LLC. (PPD)
    • 10.17.1 Company Overview
    • 10.17.2 Company Revenue
    • 10.17.3 Products
    • 10.17.4 Recent Developments
  • 10.18. IQVIA
    • 10.18.1 Company Overview
    • 10.18.2 Company Revenue
    • 10.18.3 Products
    • 10.18.4 Recent Developments
  • 10.19. Sanofi
    • 10.19.1 Company Overview
    • 10.19.2 Company Revenue
    • 10.19.3 Products
    • 10.19.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies